Novo Nordisk (NVO) Pulls the Plug on Two More Heart Drug Trials
Novo Nordisk has stopped two additional heart-drug trials, adding to setbacks in its development pipeline. The move puts more pressure on the company’s existing portfolio and upcoming clinical milestones to support its growth story.
The company has pulled the plug on two more trials involving heart drugs, according to a September 17 report. The decision expands the list of discontinued development programs but leaves the specific drug candidates, trial phases and reasons for the stoppages unclear here.
Novo Nordisk enters the development setback with a large established business: FY2025 revenue was $309.1B, up 6.4% year over year, with an 81.0% gross margin and 33.1% net margin. Those figures describe the year ended December 31, 2025, rather than the current quarter.
The immediate connection is to Novo Nordisk itself: fewer heart-drug trials mean fewer potential future products or label expansions from that part of the pipeline. The company’s existing revenue base and profitability provide operating scale, but they do not replace the clinical optionality lost when programs are discontinued.
The main uncertainty is what drove the decisions and how material the two trials were to Novo Nordisk’s broader development strategy. The next useful evidence will be the company’s explanation of the programs, updates on remaining pipeline candidates and the next quarterly disclosure of operating performance.
The trial cancellations move the pipeline risk to the downside for NVO, increasing reliance on its established portfolio and remaining clinical programs.
The cancellations narrow Novo Nordisk’s future-product optionality and make the remaining pipeline more important to sustaining growth beyond the current portfolio. The company’s FY2025 revenue of $309.1B and 33.1% net margin provide scale, but those older annual figures do not resolve the value of the discontinued programs or the strength of the replacements.
The read weakens if Novo Nordisk identifies the trials as non-core and shows that its remaining pipeline and current products can absorb the lost development optionality.
CoverageSource: Yahoo Finance · Published here THU, SEP 17 · 7:37 PM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Novo Nordisk’s FY2025 revenue of $309.1B and 33.1% net margin show a substantial established business that can remain resilient even after two heart-drug trials end.
The two additional cancellations reduce pipeline breadth, and the lack of detail on the programs leaves the downside from lost future products unresolved.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →